Price Controls Limit Access to Crucial Cures
TL/DR –
The United States, a global leader in biopharmaceutical development, is being challenged by government interventions, including provisions in the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) policies, which hinder the research and development of new treatments. According to the Association for Accessible Medicines, government intervention like the IRA and MFN threaten the innovation of novel cures and reduce the incentives for generics and biosimilars to enter the market, with an estimated one more generic entrant for every $140 million in branded sales the year prior. A University of Chicago issue brief found that price controls would raise healthcare spending by $50.8 billion over 20 years and result in 135 fewer drugs, adversely affecting the lives of 2.47 million patients.
“`html
Government Intervention Challenges US as Global Leader in Biopharmaceutical Innovation
In light of the upcoming 250th anniversary of the nation’s founding, it is essential to acknowledge the United States as the worldwide pioneer in biopharmaceutical development and innovation. However, the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) policies, which are forms of government intervention, are threatening America’s top position by impeding the research and development of new treatments and cures.
Price Controls Prove Ineffective
Price controls have proven ineffective in every industry, including biopharmaceuticals, leading to shortages and market disruptions. A 2026 report by Leerink Center for Pharmacoeconomics argues that government intervention, such as IRA and MFN policies, could hinder the development of new cures, and decrease the incentives for generics and biosimilars to enter the market. The report projects that an additional generic entrant is approximately linked to every $140 million in branded sales the previous year.
Significance of Generic and Biosimilar Drugs
The development and sustained availability of generic and biosimilar drugs play a vital role in reducing healthcare costs. According to the Association for Accessible Medicines, 90 percent of prescriptions filled in 2024 were for generics and biosimilars, providing patients with savings of $467 billion.
Price Controls and Healthcare Spending
Despite claims that price controls and increased government control in healthcare could lower costs and aid patients, a University of Chicago issue brief from August 2022 contradicts this belief. The research found that price controls could drive up healthcare spending by $50.8 billion over the next 20 years, resulting in 135 fewer drugs and adversely affecting 2.47 million patients. The Citizens Against Government Waste (CAGW) has continuously resisted government price controls on biopharmaceuticals, including MFN and the IRA Medicare “negotiations”. The organization has warned that these policies could create an “invisible graveyard” of patients who are denied essential medical treatments.
Urgent call to lawmakers
Price controls on pharmaceuticals are detrimental and could compromise the U.S.’s status as a global leader in pharmaceutical innovation. These policies pose multiple threats to the development of new cures and treatments. Consequently, lawmakers should oppose any proposals that would allow the government to dictate prices or expand its control over healthcare.
“`
—
Read More US Economic News